These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 31479925)

  • 1. A once-monthly GLP-1 receptor agonist for treatment of diabetic cats.
    Schneider EL; Reid R; Parkes DG; Lutz TA; Ashley GW; Santi DV
    Domest Anim Endocrinol; 2020 Jan; 70():106373. PubMed ID: 31479925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Hydrogel-Microsphere Drug Delivery System That Supports Once-Monthly Administration of a GLP-1 Receptor Agonist.
    Schneider EL; Hearn BR; Pfaff SJ; Reid R; Parkes DG; Vrang N; Ashley GW; Santi DV
    ACS Chem Biol; 2017 Aug; 12(8):2107-2116. PubMed ID: 28605180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacology of the glucagon-like peptide-1 analog exenatide extended-release in healthy cats.
    Rudinsky AJ; Adin CA; Borin-Crivellenti S; Rajala-Schultz P; Hall MJ; Gilor C
    Domest Anim Endocrinol; 2015 Apr; 51():78-85. PubMed ID: 25594949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy assessment of a GLP-1 mimetic: insulin glargine combination for treatment of feline diabetes mellitus.
    Scuderi MA; Ribeiro Petito M; Unniappan S; Waldner C; Mehain S; McMillian CJ; Snead EC
    Domest Anim Endocrinol; 2018 Oct; 65():80-89. PubMed ID: 30015124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug release profile of a novel exenatide long-term drug delivery system (OKV-119) administered to cats.
    Klotsman M; Anderson WH; Gilor C
    BMC Vet Res; 2024 May; 20(1):211. PubMed ID: 38762728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lymphatic uptake of the lipidated and non-lipidated GLP-1 agonists liraglutide and exenatide is similar in rats.
    Reddiar SB; Abdallah M; Styles IK; Müllertz OO; Trevaskis NL
    Eur J Pharm Biopharm; 2024 Jul; 200():114339. PubMed ID: 38789061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hydrogel Drug Delivery System Using Self-Cleaving Covalent Linkers for Once-a-Week Administration of Exenatide.
    Schneider EL; Henise J; Reid R; Ashley GW; Santi DV
    Bioconjug Chem; 2016 May; 27(5):1210-5. PubMed ID: 26930186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A long-acting C-natriuretic peptide for achondroplasia.
    Schneider EL; Carreras CW; Reid R; Ashley GW; Santi DV
    Proc Natl Acad Sci U S A; 2022 Jul; 119(30):e2201067119. PubMed ID: 35858423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exendin-4 from Heloderma suspectum venom: From discovery to its latest application as type II diabetes combatant.
    Yap MKK; Misuan N
    Basic Clin Pharmacol Toxicol; 2019 May; 124(5):513-527. PubMed ID: 30417596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of the Glucagon-like Peptide-1 Analogue Exenatide Extended Release in Cats with Newly Diagnosed Diabetes Mellitus.
    Riederer A; Zini E; Salesov E; Fracassi F; Padrutt I; Macha K; Stöckle TM; Lutz TA; Reusch CE
    J Vet Intern Med; 2016; 30(1):92-100. PubMed ID: 26700409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of immediate and prolonged GLP-1 receptor agonist administration on uric acid and kidney clearance: Post-hoc analyses of four clinical trials.
    Tonneijck L; Muskiet MHA; Smits MM; Bjornstad P; Kramer MHH; Diamant M; Hoorn EJ; Joles JA; van Raalte DH
    Diabetes Obes Metab; 2018 May; 20(5):1235-1245. PubMed ID: 29341461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety, Pharmacokinetics and Pharmacodynamics of Multiple Escalating Doses of PEGylated Exenatide (PB-119) in Healthy Volunteers.
    Cui H; Zhao CY; Lv Y; Wei MJ; Zhu Y; Ma XZ; Xia YH; Tian JH; Ma Y; Liu Y; Zhang P; Xu M
    Eur J Drug Metab Pharmacokinet; 2021 Mar; 46(2):265-275. PubMed ID: 33576936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The GLP-1 mimetic exenatide potentiates insulin secretion in healthy cats.
    Gilor C; Graves TK; Gilor S; Ridge TK; Rick M
    Domest Anim Endocrinol; 2011 Jul; 41(1):42-9. PubMed ID: 21645806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same?
    Gentilella R; Pechtner V; Corcos A; Consoli A
    Diabetes Metab Res Rev; 2019 Jan; 35(1):e3070. PubMed ID: 30156747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biological activity of AC3174, a peptide analog of exendin-4.
    Hargrove DM; Kendall ES; Reynolds JM; Lwin AN; Herich JP; Smith PA; Gedulin BR; Flanagan SD; Jodka CM; Hoyt JA; McCowen KM; Parkes DG; Anderson CM
    Regul Pept; 2007 Jun; 141(1-3):113-9. PubMed ID: 17292977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exenatide effects on gastric emptying rate and the glucose rate of appearance in plasma: A quantitative assessment using an integrative systems pharmacology model.
    Voronova V; Zhudenkov K; Penland RC; Boulton DW; Helmlinger G; Peskov K
    Diabetes Obes Metab; 2018 Aug; 20(8):2034-2038. PubMed ID: 29663628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacology of a 40 IU/ml porcine lente insulin preparation in diabetic cats: findings during the first week and after 5 or 9 weeks of therapy.
    Martin GJ; Rand JS
    J Feline Med Surg; 2001 Mar; 3(1):23-30. PubMed ID: 11716627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Magnetically-driven implantable pump for on-demand bolus infusion of short-acting glucagon-like peptide-1 receptor agonist.
    Lee SH; Min SH; Cho YC; Han JH; Kim MN; Kim CR; Ahn CH; Kim BH; Lee C; Cho YM; Choy YB
    J Control Release; 2020 Sep; 325():111-120. PubMed ID: 32619744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycemic variability in newly diagnosed diabetic cats treated with the glucagon-like peptide-1 analogue exenatide extended release.
    Krämer AL; Riederer A; Fracassi F; Boretti FS; Sieber-Ruckstuhl NS; Lutz TA; Contiero B; Zini E; Reusch CE
    J Vet Intern Med; 2020 Nov; 34(6):2287-2295. PubMed ID: 33001499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling of the Glucagon-Like Peptide-1 Receptor Agonist Exenatide to Characterize Its Antiobesity Effects in Diet-Induced Obese Mice.
    Iwasaki S; Hamada T; Chisaki I; Andou T; Sano N; Furuta A; Amano N
    J Pharmacol Exp Ther; 2017 Sep; 362(3):441-449. PubMed ID: 28698254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.